MA53875A - Traitement avec des compositions d'igg hautement sialylées - Google Patents

Traitement avec des compositions d'igg hautement sialylées

Info

Publication number
MA53875A
MA53875A MA053875A MA53875A MA53875A MA 53875 A MA53875 A MA 53875A MA 053875 A MA053875 A MA 053875A MA 53875 A MA53875 A MA 53875A MA 53875 A MA53875 A MA 53875A
Authority
MA
Morocco
Prior art keywords
treatment
highly sialylated
igg compositions
sialylated igg
compositions
Prior art date
Application number
MA053875A
Other languages
English (en)
Inventor
Santiago Arroyo
William Denney
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MA53875A publication Critical patent/MA53875A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA053875A 2018-10-11 2019-10-11 Traitement avec des compositions d'igg hautement sialylées MA53875A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744536P 2018-10-11 2018-10-11
US201962879930P 2019-07-29 2019-07-29

Publications (1)

Publication Number Publication Date
MA53875A true MA53875A (fr) 2021-08-18

Family

ID=70164359

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053875A MA53875A (fr) 2018-10-11 2019-10-11 Traitement avec des compositions d'igg hautement sialylées

Country Status (11)

Country Link
US (2) US20210353752A1 (fr)
EP (2) EP3863673A4 (fr)
JP (2) JP2022502466A (fr)
KR (2) KR20210077706A (fr)
CN (1) CN113438953A (fr)
AU (1) AU2019357842A1 (fr)
BR (1) BR112021006852A2 (fr)
CA (1) CA3115821A1 (fr)
IL (1) IL282136A (fr)
MA (1) MA53875A (fr)
WO (1) WO2020077298A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
WO2015057622A1 (fr) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
BR112022023334A2 (pt) * 2020-05-19 2022-12-20 Momenta Pharmaceuticals Inc Imunoglobulina hipersialilada
MX2023002063A (es) * 2020-08-20 2023-03-16 Momenta Pharmaceuticals Inc Glicoproteinas sialiladas.
CN116368235A (zh) * 2020-08-21 2023-06-30 动量制药公司 高唾液酸化免疫球蛋白
JP2025542423A (ja) * 2022-12-21 2025-12-25 コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション α－２，６－シアル化免疫グロブリンの眼球乾燥症または炎症性眼疾患の予防または治療用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572379A (en) * 2006-04-05 2012-06-29 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008130924A2 (fr) 2007-04-16 2008-10-30 Momenta Pharmaceuticals, Inc. Glycanes marqués par des isotopes
WO2008128220A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Libération protéolytique de glycanes
US8304250B2 (en) 2007-04-16 2012-11-06 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
WO2008128218A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Caractérisation de mélanges de n-glycanes par résonance magnétique nucléaire
CA2682750A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Procedes faisant appel a la spectrometrie de masse pour evaluer des glycanes
CA2682744C (fr) 2007-04-16 2015-10-06 Momenta Pharmaceuticals, Inc. Methodes associees a la glycosylation de surface
EP2135093B1 (fr) 2007-04-16 2015-04-15 Momenta Pharmaceuticals, Inc. Analyse de glycanes, glycopeptides ou glycoprotéines phosphorylés par imac
WO2008128219A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Analyse comparative de conformations protéiques à l'aide de spectres de rmn noesy 2d
CA2682738A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Produits de glycoproteines definis et procedes associes
WO2008128216A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Méthodes de marquage de glycanes
AU2008243007A1 (en) 2007-04-16 2008-10-30 Momenta Pharmaceuticals, Inc. Characterization of N-glycans using exoglycosidases
WO2008128230A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Produits de glycoprotéines de référence et procédés associés
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CN102239173A (zh) 2008-12-19 2011-11-09 动量制药公司 与修饰的聚糖相关的方法
WO2010071817A2 (fr) 2008-12-19 2010-06-24 Momenta Pharmaceuticals, Inc. Caractérisation de glycanes à liaison o
CN102292640B (zh) 2009-01-22 2014-07-02 动量制药公司 在来源于CHO细胞的糖蛋白产物中的含有半乳糖-α-1,3-半乳糖的N-聚糖
CA2778158A1 (fr) * 2009-10-22 2011-04-28 Eiger Health Partners, Llc Compositions, procedes de traitement et de diagnostic de troubles lies a l'auto-immunite et procede de fabrication de telles compositions
WO2011069056A2 (fr) 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Fucosylation antennaire dans des glycoprotéines de cellules cho
US9921210B2 (en) 2010-04-07 2018-03-20 Momenta Pharmaceuticals, Inc. High mannose glycans
US20150210753A1 (en) * 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2014179601A2 (fr) 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
ES2708759T3 (es) * 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
WO2015057622A1 (fr) * 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
EP3099317B1 (fr) * 2014-01-29 2021-08-04 Enzymatica AB Trypsine de la morue pour le traitement des infections microbiennes dans un sujet immunodéficient
WO2017172853A1 (fr) * 2016-03-30 2017-10-05 Ab Biosciences, Inc. Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation
CN110100007B (zh) * 2016-12-21 2024-05-28 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用

Also Published As

Publication number Publication date
US20210353752A1 (en) 2021-11-18
WO2020077298A1 (fr) 2020-04-16
KR20250160224A (ko) 2025-11-11
EP4567428A2 (fr) 2025-06-11
US20250195643A1 (en) 2025-06-19
AU2019357842A1 (en) 2021-05-13
EP3863673A4 (fr) 2023-01-11
CA3115821A1 (fr) 2020-04-16
IL282136A (en) 2021-05-31
EP3863673A1 (fr) 2021-08-18
KR20210077706A (ko) 2021-06-25
JP2025186266A (ja) 2025-12-23
CN113438953A (zh) 2021-09-24
EP4567428A3 (fr) 2025-10-01
BR112021006852A2 (pt) 2021-08-17
JP2022502466A (ja) 2022-01-11
WO2020077298A9 (fr) 2020-05-22

Similar Documents

Publication Publication Date Title
MA53875A (fr) Traitement avec des compositions d'igg hautement sialylées
IL281210A (en) Preparations for the treatment of the disease with conjugates that stimulate the immune system
EP3856173A4 (fr) Traitement d'hémopathie maligne avec des inhibiteurs de ménine
MA45192A (fr) Traitement d'association
EP3781214A4 (fr) Compositions et procédés de traitement de l'amyotrophie spinale
IL281809A (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EP3875542A4 (fr) Composition d'émulsion de silicone
EP3820490A4 (fr) Compositions d'aav
IL268905B (en) Phage therapy
EP3827837A4 (fr) Composition visant à prévenir et traiter des maladies liées au système immunitaire
EP3820980A4 (fr) Compositions d'esterquats
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP4085053A4 (fr) Traitement du cancer avec des inhibiteurs de cdk12/13
EP3706558A4 (fr) Compositions et procédés d'aquaculture
UA120999C2 (uk) Естери оксаборолу та їх використання
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3763327A4 (fr) Dispositif de traitement d'aorte
EP3344071A4 (fr) Compositions combinées pour réguler des niveaux de glycémie, l'hépatoprotection, et pour la prévention et le traitement d'états médicaux associés
EP3769784A4 (fr) Composition de suppression de l'inflammation
EP3632430A4 (fr) Agent de prévention ou de traitement de l'ataxie spinocérébelleuse
GB202020354D0 (en) Compositions for the treatment of disease with immune stimulatory conjugates
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique
EP3809062A4 (fr) Vanne d'arrêt
IL286818A (en) Mirikizumab for use in a method of treating crohns disease